Visit Kalorama Information’s NEW store on scienceandmedicinegroup.com for our most recent 2025 market reports! 

Visit New Store

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

PharmaceuticalsX

Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Vaccines
Drug Delivery
Over-the-Counter
Drug Discovery
Cancer Treatment
Manufacturing & Packaging
Prescription Drugs

  • New Anticoagulant Therapies: A Market Briefing
    $895.00 – $1,790.00
    There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the […]
    October 1, 2004
  • U.S. Market for Over-the-Counter Gastrointestinal Products, 2nd Edition, The
    $1,995.00 – $5,990.00
    The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents […]
    August 1, 2004
  • Ambulatory Infusion Pumps in Pain Management: A Market Briefing
    $895.00 – $1,790.00
    After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a […]
    August 1, 2004
  • Pharmaceutical Outsourcing Opportunities Post Launch: Contract Manufacturing, and Sales and Marketing
    $3,500.00 – $7,000.00
    After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to […]
    July 1, 2004
  • Early Stage Drug Discovery 2004: Combi-chem & High Throughput Screening Revisited
    $2,995.00 – $5,990.00
    Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to […]
    June 1, 2004
  • Market for Generic Biologics: Issues, Trends, and Market Potential, The
    $1,500.00 – $3,000.00
    Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. […]
    June 1, 2004
  • Growth Factor Inhibitors: Markets and Opportunities for a Growing Pipeline
    $3,500.00 – $7,000.00
    Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow […]
    March 1, 2004
  • Medicare Reform and the Pharmaceutical Industry: Implications of the Medicare Prescription Drug Improvement and Modernization Act of 2003
    $795.00 – $1,590.00
    The hard-fought battle over Medicare’s prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all […]
    March 1, 2004
  • Cardiovascular Disease: The 45 Market in the United States for Drugs and Medical Devices
    $2,995.00 – $5,990.00
    Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of […]
    March 1, 2004
  • Worldwide Market for Prescription Dermatological Drugs - 4th Edition, The
    $3,500.00 – $7,000.00
    This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fourth time Kalorama Information has comprehensively studied the dermatology markets. For this latest edition, Kalorama completely re-evaluated the market from the […]
    February 1, 2004